Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis
To assess the efficacy of pasireotide in the reduction of clinically relevant postoperative digestive leakage after CRS plus HIPEC compared to placebo
Peritoneal Carcinomatosis
DRUG: Pasireotide 0.9 MG/ML|OTHER: Saline water
postoperative digestive leakage, The rate of clinically relevant (NCI CTCAE v5 â‰¥ grade 3) postoperative digestive leakage at 97 days, 97 days
To assess the efficacy of pasireotide in the reduction of clinically relevant postoperative digestive leakage after CRS plus HIPEC compared to placebo